Anesiva, Inc. (Anesiva) is a biopharmaceutical company focused on the development and commercialization of therapeutic treatments for pain management. Its portfolio of products includes Zingo powder intradermal injection system, which was approved by the United States Food and Drug Administration (FDA) in August 2007, and Adlea, which is a long-acting, site-specific, non-opioid analgesic, being developed for moderate to severe pain, and has completed multiple Phase II trials in post-surgical, musculoskeletal and neuropathic pain. In October 2007, it announced that its Phase III clinical trial in adults requested by FDA met its primary endpoint. (Source: 10-K)
QSV Biologics, Ltd. is a North American based cGMP biologics contract manufacturer providing mammalian cell culture, microbial fermentation and purification services for the production of protein therapeutics, monoclonal antibodies, vaccines and diagnostics. Our facility has a 10 year track record and is licensed for cGMP manufacture of pre-clinical, clinical and commercial supply. QSV recently underwent a comprehensive GMP compliance audit by Health Canada's Health Products and Food Branch Inspectorate (HPFBI) and was found to be compliant with all applicable regulations and guidelines. QSV's market consists of Canadian, U.S., Australian, Asian and European biotechnology firms with protein therapeutics in development. As a dedicated biopharmaceutical contract manufacturer, QSV provides the following services: cGMP Microbial Fermentation Microbial Process Development Upstream and Downstream Mammalian Cell Culture Process Development Upstream and Downstream cGMP Cell Bank Development & Storage Analytical Development Process & Analytical Validation Process Scale Up cGMP Document Services Technology Transfer Quality is your first consideration when selecting a contract manufacturer. Quality is our first priority! More information can be obtained by contacting: Richard Hetrick Business Development Phone: (484) 678 - 4820 Phone: (780) 438 - 7143 Fax: (610) 873 - 8453 Email: rhetrick@qsvbiologics.com
Scion Pharmaceuticals, Inc. discovers and develops small molecule drugs that selectively regulate ion channels, a well-established class of pharmaceutical targets with potential application for a wide range of major diseases. Scion applies an innovative ion channel drug discovery strategy that integrates functional biology and medicinal chemistry, and is enabled by its proprietary high-throughput electrophysiology assay (HTEPÔ). This approach allows the Company to evaluate ion channel subtype target function and effects of molecules on ion channels at the earliest stages of the drug discovery process. Scion is initially utilizing this approach to discover drugs for the treatment of cardiovascular and CNS disorders, with focus on atrial fibrillation and pain, respectively. Currently, the Company holds over 70 issued U.S. patents as well as foreign counterparts in many other countries.
Launched in December of 1996, Phytomedics is a privately owned Company that operates from its corporate headquarters in Jamesburg, NJ. Most of the Company's R&D takes place at the Biotech Center at Rutgers University, under the leadership of Dr. Ilya Raskin, a Company co-founder. Phytomedics signed a broad research and licensing agreement with Rutgers University that allows the Company to exclusively license its core technologies and products. This affiliation with Rutgers enables the Company to operate at a low expense rate while using state-of-the-art laboratories and greenhouses and accessing the diverse expertise available in a leading university. Phytomedics is funded by a broad international consortium of life science investors including Swiss based inventages venture capital GmbH (life ventures by Nestle), U.S. based Burrill & Company, Israeli based Polar Investments Ltd and Biotech M.A.H. Plant Genomic Fund (jointly run by Makhteshim Agan Industries and Hazera Genetics), and Nestir SA, the venture arm of the giant South American agro-industrial conglomerate, the Arlei group.
About Norak Biosciences, Inc. Norak Biosciences, Inc., headquartered in Research Triangle Park, NC, is a private biotechnology company. Norak is utilizing its proprietary Transfluor technology to become a world leader in the discovery and development of drugs that regulate G protein- coupled receptors.
Cerep's mission is to provide pharmaceutical companies with high quality services in drug discovery and drug development. Cerep provides, both in Europe and in the United States, solutions allowing faster and cost effective drug discovery by identifying at early stages the most promising drug candidates as well as eliminating those compounds likely to fail in development.
Cyclacel Pharmaceuticals, Inc. (Cyclacel) is a development-stage biopharmaceutical company engaged in the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. The Company markets, directly in the United States, Xclair Cream for radiation dermatitis, and Numoisyn Liquid and Numoisyn Lozenges for xerostomia through its wholly owned subsidiary, ALIGN Pharmaceuticals, LLC (ALIGN). Cyclacel focuses primarily on the development of orally available anticancer agents that target the cell cycle with the aim of slowing the progression or shrinking the size of tumors. The Company has been focusing on the cell cycle since its inception. On January 13, 2009, it announced that the Company began treating patients in a Phase II, open label, single arm, multicenter clinical trial of sapacitabine in patients with non-small cell lung cancer (NSCLC) who have had one prior chemotherapy. (Source: 10-K)
MediQuest Therapeutics is a privately held specialty pharmaceutical company headquartered in Bothell, Washington. MediQuest is a specialty pharmaceutical company developing first- and best- in-class topical therapies to treat patients suffering from inflammatory and infectious diseases. Using a proprietary drug delivery technology, MediQuest can deliver a topical therapy through thickened or diseased skin and nails. The Company's innovative treatment approach and proprietary drug delivery system have generated a robust late-stage clinical pipeline aimed at treating inflammatory/infectious diseases and satisfying unmet medical needs. For information about Raynauds, visit www.mqti.com/raynauds.
Novocell, Inc. is a stem cell engineering company dedicated to creating, delivering and commercializing cell and drug therapies to treat diabetes and other chronic diseases. Novocell uses its proprietary cell encapsulation technology and expertise in cell implantation to develop a renewable source of specialized cells for treatment of cellular diseases. Novocell, Inc. is headquartered in San Diego, California with additional research operations in Athens, Georgia. The company was founded in 1999 and merged with CyThera and Bresagen in 2004.
http://www.siriontherapeutics.com
Sirion Therapeutics is a privately held biopharmaceutical company pursuing the discovery, development, and commercialization of products addressing unmet medical needs in the protection and preservation of eyesight. Sirion's product portfolio includes: Durezol, a topical steroid for postoperative inflammation and pain and in development for uveitis; ganciclovir, a topical antiviral in development for herpetic keratitis; cyclosporine, a topical immunomodulator in development for dry eye; and fenretinide, a first-in-class oral vitamin A binding protein antagonist in development for geographic atrophy associated with dry AMD.
Aton Pharma, Inc. is a privately held biopharmaceuticals company that was founded in 2001 by a group of leading cancer investigators to develop and commercialize novel therapeutics for cancer and other diseases that were discovered in the respective laboratories of co-founders Ronald Breslow, Ph.D. and Paul A. Marks, M.D. at Columbia University and Memorial Sloan Kettering Cancer Center. The company is engaged in the discovery and development of innovative therapeutics, in the emerging field of chromatin science, for cancer and other diseases with an unmet medical need.
KAI Pharmaceuticals is a biology-based, product-driven, drug discovery and development company leveraging protein kinase C (PKC) signaling to generate a portfolio of clinical and preclinical drug candidates for the treatment of acute cardiovascular and other important human diseases. The company is applying its core expertise in the biology of translocation of PKC isozymes to develop highly specific activators and inhibitors of PKC. KAI has received ,Fast Track' designation for its lead drug candidate, KAI-9803, currently being investigated in a Phase I/II clinical trial as a treatment to prevent ischemia induced reperfusion injury in acute myocardial infarction.
Conforma Therapeutics, a San Diego-based biopharmaceutical company, is focused on the design and development of novel drugs for the treatment of cancer. Conforma's internal discovery efforts have been focused on drugs that target the cellular HSP90 family of molecular "chaperones" that control protein shape or conformation, including that of key signaling molecules involved in the growth and survival of tumor cells.
Alantos Pharmaceuticals is a chemistry-driven biopharmaceutical company with a proprietary pipeline of small molecule drugs focused in the area of type II diabetes and osteoarthritis / inflammation. With locations in Cambridge, Massachusetts and Heidelberg, Germany, Alantos Pharmaceuticals employs 45 people.
Cetek Corporation is a biopharmaceutical company engaged in the discovery and early development of novel cancer therapeutics based on the convergent application of its two core technologies: CE AssayÔ and the Company's natural-product based drug sources. The broadly applicable CE AssayÔ is Cetek's proprietary, high-throughout capillary electrophoresis technology that enables the rapid screening of difficult to assay drug targets as well as conventional targets. Interfacing with CE AssayÔ is Cetek's proprietary natural product extract library and its emerging ChemSelectÔ library of single-compounds and natural product-like synthetic derivatives. The application of these technologies is driving Cetek's growing oncology portfolio and creating opportunities for strategic alliances in multiple therapeutic areas. Cetek expects its first proprietary product to enter clinical trials in 2007. Cetek was founded in 1996. Historically the Company had focused on applying its CE AssayÔ technology on a fee-for-service basis, screening targets involved in a wide array of disease indications. Its clients have included, Johnson & Johnson, Schering Plough, Fujisawa and Millennium. More recently Cetek has added a world class natural product drug source, further strengthened its preclinical technologies, and adopted a dual strategy which adds proprietary in-house drug discovery and development. Cetek has assayed over 8 million compounds since 2001, screening more than 150 validated drug targets. The technology has identified multiple lead compounds for both clients and its own internal discovery initiatives.
Inotek Pharmaceuticals is a multi-national biopharmaceutical firm focused on discovery research and the development of novel pharmaceutical technologies with potential applications in critical care, surgery, trauma, transplantation, and auto-immune diseases. The Company has a comprehensive and integrated development platform focused on the prevention of cellular necrosis, organ inflammation, and gram negative infection. Candidate agents target free radical production, various free radical medicated cellular processes, and microbial stimulation of inflammation. Medical targets include gingivitis, colitis, psoriasis, diabetes, stroke, myocardial infarction, arthritis, pneumonia, and urinary tract infection. Inotek's business strategy is to develop and manufacture its compounds and biologics through human clinical trials and partner products for commercialization and marketing. The Company operates R&D and manufacturing facilities in the United States, the United Kingdom, Hungary and Israel. The Company's future expansion will be driven by internal capital resources, strong and growing extramural research and development support, strategic partnerships with mid-size and fully-integrated pharmaceutical firms focused on the development of individual technologies, and venture capital infusions to support the formation and development of foreign subsidiaries.
PainCeptor Pharma is a biopharmaceutical company developing next generation therapeutic drugs for the treatment of chronic and acute pain.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory